Targeted immune activation

Restoring immune function

All healthy individuals continuously produce cancer cells throughout their lives. These cells occur on an ongoing basis and because they develop from within the body, they are referred to as autologous. Malignant cells result from the effects of mutations and viruses and exposure to carcinogens ranging from radiation or, tobacco smoke, to pesticides, and food colorings and preservatives, just to mention a few.
It is the primary task of the cellular immune system to detect these cancer cells early and destroy them. When cancer occurs, the immune response is suppressed, or there has been an excessive exposure to a carcinogen. Impaired immune function often involves a drop in the number and/or the function of immune cells available to effectively detect or kill cancer cells.

Combating cancer

Certain antigen-presenting cells are essential for mounting an effective immune response against neoplastic transformation. These cells migrate through peripheral tissues, performing immunosurveillance by detecting aberrant or transformed cells. They are also capable of identifying cells under oncogenic stress, such as those chronically infected with oncogenic viruses (e.g., persistent HPV infection in cervical epithelium, which carries malignant potential).
Upon recognition of a potentially malignant or transformed cell, the antigen-presenting cell migrates to a regional lymph node, where it displays the antigenic signature of the target cell to lymphocytes, initiating an adaptive immune response aimed at its elimination.

Immune Therapy

Studies have demonstrated that functionally active antigen-presenting cells can be introduced into the body via therapeutic vaccination. In individuals with malignant disease, administration of these immune-stimulatory cells reactivates immunosurveillance mechanisms and enhances the immune system’s ability to recognize and mount a response against tumor-associated antigens.
These therapeutic cells are derived from the patient’s own leukocytes (therefore classified as autologous). Following a routine blood collection, the sample is processed in a specialized laboratory, where trained cellular therapy specialists isolate specific immune precursors—primarily monocytes. These precursors are then cultured under controlled conditions and, over approximately seven days, differentiated into a highly active population of immunomodulatory cells. The resulting cell-based product is re-administered to the patient via simple intradermal injections.

Our approach

The initial phase involves inducing a febrile response—either through whole-body hyperthermia or localized thermal therapy—in conjunction with an autologous immune-cell-based vaccine. Under normal physiological conditions, fever is regulated by thermoregulatory centers in the brainstem, which are also responsible for maintaining homeostatic core temperature. This elevation in body temperature acts as a critical trigger for the activation and amplification of the immune response, a key factor in combating pathological processes.

The subsequent phase includes administration of a personalized cellular immunotherapy, designed to train the immune system to recognize and target malignant cells. These injections are typically well tolerated, with minimal adverse effects apart from a transient febrile response, usually occurring on the day of administration and resolving within 4 to 24 hours.